MAL Promoter Hypermethylation as a Prognostic Marker in Gastric Cancer
Author Information
Author(s): Buffart T E, Overmeer R M, Steenbergen R D M, Tijssen M, van Grieken N C T, Snijders P J F, Grabsch H I, van de Velde C J H, Carvalho B, Meijer G A
Primary Institution: VU University Medical Center, Amsterdam, The Netherlands
Hypothesis
The study aims to analyze the prevalence of MAL promoter hypermethylation in gastric cancers and its association with mRNA expression and clinicopathological data.
Conclusion
MAL promoter hypermethylation is frequent in gastric cancers and correlates with better survival, suggesting its potential as a prognostic marker.
Supporting Evidence
- MAL promoter hypermethylation was detected in 80.2% of gastric cancers.
- Patients with M2 methylated tumors had significantly better survival rates.
- Hypermethylation of M2 correlated with downregulation of MAL expression.
Takeaway
This study found that a specific change in the DNA of stomach cancer cells can help predict how well patients will do after treatment.
Methodology
The study analyzed DNA from 202 gastric adenocarcinomas and 22 normal gastric mucosae using real-time methylation-specific PCR.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the selection of archival samples.
Limitations
The study was retrospective and used archival material, which may limit the generalizability of the findings.
Participant Demographics
The study included gastric adenocarcinoma samples from patients without prior chemotherapy or radiotherapy.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website